Femasys (FEMY) shares moved higher after the New York Times reported that President Trump is expected to announce a proposal on Thursday aimed at expanding access to in vitro fertilization. Femasys develops the FemaSeed Intratubal Insemination, an infertility treatment. The stock in midday trading is up 30%, or 17c, to 72c.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FEMY:
- VTI ETF News, 10/3/2025
- Strategic Partnership with Kebomed Boosts Femasys’ European Expansion for FemBloc
- Femasys announces partnership with Kebomend to commercialize FemBloc
- Femasys partners with Medical Electronic Systems for FemSperm kit
- Femasys expands FemSperm product line with Insemination Prep Kit